microdose glp 1 perimenopause PSA for all the women on GLP-1s and hormone replacement therapy (HRT MENOPAUSAL WEIGHT GAIN AND GLP1

Equally effective as GLP-1 treatments

Studies indicating risks associated with Saxenda: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (JAMA) Medication-Induced Gastroparesis: A Case Report (Journal of Investigative Medicine High Impact Case Reports) Liraglutide-induced Acute Gastroparesis (Cureus): A case study of a 52-year-old man with well-controlled diabetes who experienced acute gastroparesis after starting liraglutide

For most medications, this delay is clinically insignificant

The overall extent of glucagon-mediated energy expenditure enhancement is reliant on multiple intact systemic components which include: hepatic expression of GcgR, FGF21, farsenoid X receptor (FXR), and alanine transaminase (ALT)

Symptoms include: Diarrhea (typically watery but not bloody) Low-grade fever Nausea Occasional muscle aches or headache Stomach cramps and pain Vomiting The vomiting and diarrhea are the largest concerns, as patients can quickly become dehydrated

In a seminal study by Day et al., 48 several co-agonists with different GLP-1-to-GCG receptor ratios were investigated in murine models and the optimal balance was suggested to be a co-agonist with equal potency on both receptors